Please assess the completion status of the following clinical trial:

Trial Title: Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to the hospital for a COPD exacerbation~* FEV1 less than 60% of predicted level~* At least 10 pack years of smoking~Exclusion Criteria:~* Any uncontrolled systemic disease~* Known hypersensitivity to zileuton~* Asthma~* Lobar pneumonia or pulmonary edema~* Interstitial lung disease~* Medical condition that is likely to limit survival to less than 30 days at the time of study entry~* History of liver disease~* Current use of theophylline~* Participation in another clinical trial in the COPD Clinical Research Network~* Incarceration~* Institutionalization~* Pregnant~* History of a suicide attempt~* Prior inpatient admission for a psychiatric disorder~* Bipolar disorder~'

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zileuton (Type: ACTIVE_COMPARATOR): Zileuton (Zyflo, 600 mg 4 times a day)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).